Rare Mutation: Immune to Viruses
Summary of the Article: Broad-Spectrum Antiviral Therapy Shows Promise
This article details a promising new antiviral therapy developed by Dr. Bogunovic and his team, inspired by a surprising observation: people with a rare genetic condition called ISG15 deficiency seem to be remarkably resistant to a wide range of viruses.
Here’s a breakdown of the key points:
The Inspiration: Individuals lacking the ISG15 protein exhibit a broad antiviral “superpower,” resisting many viruses including influenza and SARS-CoV-2.
The Therapy: Bogunovic’s therapy aims to mimic this protection, but in a controlled and temporary way. Rather of fully disabling ISG15 (which has negative side effects), it stimulates the production of 10 key proteins responsible for the antiviral effect.
How it effectively works: The therapy uses mRNA technology (similar to COVID vaccines) to deliver instructions to cells to produce these 10 proteins,packaged within lipid nanoparticles.
Promising Results: In animal studies (hamsters and mice), the therapy prevented viral replication of influenza and SARS-cov-2 and reduced disease severity. In cell cultures, it has shown effectiveness against all viruses tested so far.
Pandemic Preparedness: The therapy is designed to be broad-spectrum, possibly protecting against unknown future viruses, making it a valuable tool for pandemic preparedness. It also doesn’t interfere with the body’s ability to develop long-term immunity. Current challenges: The delivery method (nanoparticles) needs optimization to ensure sufficient protein production in the lungs for human use.
in essence, this research offers a potentially revolutionary approach to antiviral defense – a preemptive strike against a wide range of viral threats, rather than relying on virus-specific treatments.